Collegium Pharmaceutical (NASDAQ:COLL) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Friday.

COLL has been the subject of several other research reports. Piper Jaffray Companies restated a “buy” rating and issued a $14.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, September 8th. HC Wainwright initiated coverage on shares of Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a “buy” rating and a $21.00 price target for the company. Jefferies Group restated a “buy” rating and issued a $15.00 price target on shares of Collegium Pharmaceutical in a research report on Thursday, September 21st. Needham & Company LLC restated a “buy” rating and issued a $25.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, October 6th. Finally, Zacks Investment Research upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a research report on Monday, November 13th. One investment analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $23.33.

Shares of Collegium Pharmaceutical (NASDAQ COLL) opened at $19.06 on Friday. Collegium Pharmaceutical has a one year low of $7.37 and a one year high of $20.92. The company has a market cap of $619.01, a P/E ratio of -6.40 and a beta of 0.41.

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, November 8th. The specialty pharmaceutical company reported ($0.45) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.28. Collegium Pharmaceutical had a negative net margin of 447.83% and a negative return on equity of 77.11%. The business had revenue of $11.95 million during the quarter, compared to analyst estimates of $5.31 million. During the same period in the prior year, the business earned ($1.13) earnings per share. The business’s quarterly revenue was up 2814.6% on a year-over-year basis. research analysts anticipate that Collegium Pharmaceutical will post -2.52 EPS for the current fiscal year.

In related news, CEO Michael Thomas Heffernan sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $15.53, for a total value of $776,500.00. Following the completion of the sale, the chief executive officer now owns 558,987 shares in the company, valued at approximately $8,681,068.11. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Alison B. Fleming sold 4,601 shares of the stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $17.25, for a total transaction of $79,367.25. Following the completion of the sale, the insider now owns 28,513 shares of the company’s stock, valued at approximately $491,849.25. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,058,630 shares of company stock valued at $18,264,360. 25.76% of the stock is owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in COLL. Voya Investment Management LLC purchased a new stake in Collegium Pharmaceutical in the 2nd quarter worth approximately $125,000. Credit Suisse AG lifted its position in Collegium Pharmaceutical by 9.4% in the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 1,173 shares in the last quarter. Nationwide Fund Advisors lifted its position in Collegium Pharmaceutical by 27.8% in the 2nd quarter. Nationwide Fund Advisors now owns 12,889 shares of the specialty pharmaceutical company’s stock worth $161,000 after buying an additional 2,802 shares in the last quarter. JPMorgan Chase & Co. purchased a new stake in Collegium Pharmaceutical in the 3rd quarter worth approximately $192,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Collegium Pharmaceutical in the 2nd quarter worth approximately $198,000. Institutional investors own 79.98% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/12/29/collegium-pharmaceutical-coll-raised-to-strong-buy-at-bidaskclub.html.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.